Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effects of scopolamine in healthy volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 1, 2001, Pages 51-60

  Ebert, Ulrike ^a   Grossmann, Matthias ^a   Oertel, Reinhard ^a   Gramatté, Thomas ^a,b   Kirch, Wilhelm ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b APOGEPHA Arzneimittel GmbH Dresden   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SCOPOLAMINE;

ADULT; ALPHA RHYTHM; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BETA RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTA RHYTHM; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; ELECTROENCEPHALOGRAM; FRONTAL LOBE; HUMAN; MALE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SENILE DEMENTIA; THETA RHYTHM;

ADULT; ALPHA RHYTHM; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; MODELS, BIOLOGICAL; MUSCARINIC ANTAGONISTS; PLACEBOS; SCOPOLAMINE;

EID: 0034747713     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122009836     Document Type: Article

References (36)

1. Human memory and the cholinergic system
2. Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine
3. Physostigmine and recent memory: Effects in young and aged non-human primates
4. Cholinesterase inhibition in the scopolamine model of dementia
5. Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
6. An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg s.c.
7. Effects of scopolamine (0.25-0.75 mg i.m.) on the quantitative EEG and the neuropsychological status of healthy volunteers
8. Effects of a single intravenous dose of scopolamine on the quantitative EEG in Alzheimer's patients and age-matched controls
9. Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration
10. Effects of physostigmine on scopolamine induced changes in quantitative electroencephalogram and cognitive performance
11. Anticholinergic drug effects on quantitative electroencephalogram, visual evoked potential, and verbal memory
12. Human flash-VEP and quantitative EEG are independently affected by acute scopolamine
13. Synergistic anticholinergic and antiserotonergic effects in humans
14. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
15. Kinetic-dynamic modeling in clinical psychopharmacology
16. Determination of scopolamine in human serum by gas chromatography-ion trap tandem mass spectrometry
17. The ten-twenty electrode system of the International Federation
18. Relation between psychometric tests and quantitative topographic EEG in pharmacology
19. Empfehlungen der Deutschen EEG-Gesellschaft fur das Mapping von EEG-Parametern (EEG- und EP-Mapping)
20. Noncompartmental analysis based on statistical moment theory
21. A semiparametric approach to physiological flow models
22. Kinetics of pharmacologic response
23. A comparison of spectral edge, delta power, and bispectral index as EEG measures of alfentanil, propofol, and midazolam drug effect
24. The effects of transdermal scopolamine on autonomic nervous activity during sleep
25. Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate
26. Pharmacokinetics of scopolamine during caesarean section: Relationship between serum concentration and effect
27. Pharmacokinetics and oral bioavailability of scopolamine in normal subjects
28. Pharmacokinetics and clinical effects of scopolamine in caesarean section patients
29. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate
30. Brain cholinergic dysfunction and memory in aged rats
31. Age-related alterations in neurotransmitter receptors: An electrophysiological and biochemical analysis
32. Cholinergic receptor loss in brains of aging mice
33. Alterations in atropine sites of the brain of rats as a function of age
34. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls: A dose-response study
35. The cholinergic hypothesis of geriatric memory dysfunction
36. Cholinergic modulation, visual function and Alzheimer's dementia